Shaanxi Kanghui Pharm Co Ltd - Asset Resilience Ratio
Shaanxi Kanghui Pharm Co Ltd (603139) has an Asset Resilience Ratio of 0.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603139 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Shaanxi Kanghui Pharm Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 603139 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Shaanxi Kanghui Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 603139 current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥252.20K | 0.01% |
| Total Liquid Assets | CN¥252.20K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Shaanxi Kanghui Pharm Co Ltd maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shaanxi Kanghui Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shaanxi Kanghui Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Piramal Pharma Limited
NSE:PPLPHARMA |
Drug Manufacturers - Specialty & Generic | 0.73% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Shaanxi Kanghui Pharm Co Ltd (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Shaanxi Kanghui Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | CN¥252.20K ≈ $36.90K |
CN¥1.81 Billion ≈ $265.51 Million |
-0.01pp |
| 2024-12-31 | 0.02% | CN¥359.18K ≈ $52.56K |
CN¥1.89 Billion ≈ $276.25 Million |
-0.13pp |
| 2023-12-31 | 0.15% | CN¥3.02 Million ≈ $441.85K |
CN¥2.05 Billion ≈ $300.23 Million |
-0.10pp |
| 2022-12-31 | 0.25% | CN¥4.50 Million ≈ $658.73K |
CN¥1.82 Billion ≈ $266.57 Million |
-6.18pp |
| 2021-12-31 | 6.42% | CN¥119.47 Million ≈ $17.48 Million |
CN¥1.86 Billion ≈ $272.21 Million |
+2.19pp |
| 2020-12-31 | 4.23% | CN¥55.47 Million ≈ $8.12 Million |
CN¥1.31 Billion ≈ $191.87 Million |
-12.75pp |
| 2019-12-31 | 16.98% | CN¥192.00 Million ≈ $28.10 Million |
CN¥1.13 Billion ≈ $165.45 Million |
-- |
About Shaanxi Kanghui Pharm Co Ltd
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical intermediates in China. It is involved in the research, development, production, and sale of traditional Chinese medicine preparations; research and development of prepared slices of Chinese medicinal herbs and pharmaceutical intermediates; and pharmaceutical distribution of biolo… Read more